Last $5.01 USD
Change Today -0.14 / -2.72%
Volume 805.2K
PACB On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

pacific biosciences of calif (PACB) Snapshot

Open
$5.17
Previous Close
$5.15
Day High
$5.24
Day Low
$4.88
52 Week High
01/21/14 - $8.20
52 Week Low
09/23/13 - $3.32
Market Cap
353.9M
Average Volume 10 Days
474.4K
EPS TTM
$-1.12
Shares Outstanding
70.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PACIFIC BIOSCIENCES OF CALIF (PACB)

pacific biosciences of calif (PACB) Related Bloomberg News

View More Bloomberg News

pacific biosciences of calif (PACB) Related Businessweek News

View More BusinessWeek News

pacific biosciences of calif (PACB) Details

Pacific Biosciences of California, Inc. develops, manufactures, and markets an integrated platform for genetic analysis in the deoxyribonucleic acid (DNA) sequencing market. The company is engaged in developing a single molecule real-time (SMRT) technology for the detection of biological processes. Its SMRT technology is used to study the synthesis, composition, structure, and regulation of DNA, as well as to record individual biochemical events as they occur. The company’s product includes the PacBio RS II high resolution genetic analyzer, an instrument that conducts, monitors, and analyzes single molecule biochemical reactions in real time. Its PacBio RS high resolution genetic analyzer consists of an instrument platform that uses its proprietary consumables, such as SMRT Cells and reagent kits to prepare and sequence DNA samples. The company’s customers include genome centers, genomics service providers, and pharmaceutical and agricultural companies, as well as clinical, government, and academic institutions. Pacific Biosciences of California, Inc. markets its products through a direct sales force in North America and Europe, as well as through distributors in Asia. The company, formerly known as Nanofluidics, Inc., was founded in 2000 and is headquartered in Menlo Park, California.

318 Employees
Last Reported Date: 03/14/14
Founded in 2000

pacific biosciences of calif (PACB) Top Compensated Officers

Executive Chairman, Chief Executive Officer, ...
Total Annual Compensation: $1.0
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.0
Senior Vice President of Market Development
Total Annual Compensation: $361.5K
Senior Vice President of Research and Develop...
Total Annual Compensation: $361.5K
Compensation as of Fiscal Year 2013.

pacific biosciences of calif (PACB) Key Developments

Pacific Biosciences of California, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2014

Pacific Biosciences of California, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue of $11,425,000, operating loss of $18,302,000, net loss of $19,136,000 or $0.27 per basic and diluted share compared to the total revenue of $6,048,000, operating loss of $19,997,000, net loss of $20,471,000 or $0.33 per basic and diluted share for the same quarter a year ago. For the six months period, the company reported total revenue of $23,067,000, operating loss of $36,547,000, net loss of $38,022,000 or $0.55 per basic and diluted share compared to the total revenue of $11,626,000, operating loss of $40,604,000, net loss of $41,575,000 or $0.7 per basic and diluted share for the same period a year ago.

Pacific Biosciences of California, Inc., Q2 2014 Earnings Call, Jul 24, 2014

Pacific Biosciences of California, Inc., Q2 2014 Earnings Call, Jul 24, 2014

Pacific Biosciences and GenDx Initiate Co-Marketing Activities for Full-Length HLA Gene Sequencing Products

Pacific Biosciences of California, Inc., and GenDx announced a co-marketing agreement to offer products for full-length HLA gene sequencing. The Human Leukocyte Antigen (HLA) system consists of a large family of highly variable genes and allelic variants that forms the basis of the human immune system. High-resolution HLA typing and sequencing of the complete gene enables determination of even the smallest variations between HLA alleles. HLA allele-specific genotyping is critical for autoimmune disease-association studies, drug hypersensitivity research and other applications. Thus, there has been an ever growing interest in characterizing the HLA genes in their entirety. GenDx, which currently offers reagents for the amplification of full-length, Class I HLA genes, will offer a version of its NGSgo(R) reagent line with barcoded primers developed with Pacific Biosciences for sequencing on the PacBio RS II DNA sequencing system. Using the GenDx NGSengine(R) software package to analyze data from the PacBio system provides customers with a highly accurate, allele-level HLA typing solution. This new reagent kit will allow the pooling of full-length, Class I HLA genes from multiple samples into a single sequencing run.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PACB:US $5.01 USD -0.14

PACB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Affymetrix Inc $8.27 USD -0.26
Fluidigm Corp $26.33 USD -1.77
IntelliCell BioSciences Inc $0.0014 USD 0.0001
Luminex Corp $19.21 USD -0.72
Sequenom Inc $3.14 USD -0.11
View Industry Companies
 

Industry Analysis

PACB

Industry Average

Valuation PACB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.9x
Price/Book 6.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PACIFIC BIOSCIENCES OF CALIF, please visit www.pacificbiosciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.